Pharmacological treatment of prediabetes
Pro Research Analysisby 
Searched over 200M research papers
Pharmacological Treatment Options for Prediabetes
Metformin as First-Line Pharmacological Therapy for Prediabetes
Metformin is widely recognized as the first-line pharmacological treatment for prediabetes, with strong evidence supporting its ability to delay or prevent the progression to type 2 diabetes. Large clinical trials have shown that metformin improves insulin sensitivity and beta-cell function, and is generally well-tolerated and safe for long-term use. However, its effect is less pronounced than intensive lifestyle interventions, and combining metformin with lifestyle changes does not appear to provide significant additional benefit over lifestyle changes alone Mangan2018Rendell2020Hostalek2015.
Other Established and Emerging Pharmacological Agents
Thiazolidinediones (e.g., Pioglitazone)
Thiazolidinediones like pioglitazone have also demonstrated efficacy in improving insulin sensitivity and beta-cell function in prediabetic individuals. Pioglitazone can reduce fasting and postprandial glucose levels, but may be associated with weight gain .
SGLT2 Inhibitors
SGLT2 inhibitors, such as dapagliflozin and empagliflozin, are emerging as promising options for prediabetes management. These agents not only lower blood glucose but also improve insulin sensitivity, reduce adipose tissue insulin resistance, and may even reverse brain insulin resistance, which could have additional metabolic benefits Velazquez2022Rendell2020Kullmann2021.
DPP-4 Inhibitors
DPP-4 inhibitors like saxagliptin have been studied for prediabetes, showing improvements in insulin sensitivity and adipose tissue insulin resistance, though their impact on weight is minimal .
GLP-1 Receptor Agonists
GLP-1 receptor agonists, such as exenatide, have shown superior efficacy compared to metformin in achieving remission of prediabetes, particularly in patients with polycystic ovary syndrome (PCOS). These agents improve postprandial insulin secretion and may be especially beneficial for overweight or obese individuals Rendell2020Tao2020.
Other Agents and Natural Products
Newer agents like Subetta® and combinations of natural products such as 1-deoxynojirimycin (DNJ) and morin have shown potential in improving glucose intolerance and insulin resistance in prediabetes. Subetta® may be more effective for impaired glucose tolerance, while metformin remains more effective for impaired fasting glucose. The combination of DNJ and morin has demonstrated significant prevention of diabetes progression in animal models by targeting insulin resistance and lipid metabolism Mkrtumyan2024Ren2023.
Comparative Effectiveness and Patient Considerations
While lifestyle modification remains the cornerstone of prediabetes management, pharmacological interventions are particularly valuable for individuals at high risk of progression to diabetes or those unable to achieve sufficient lifestyle changes. Metformin is the most established option, but other agents such as SGLT2 inhibitors, GLP-1 receptor agonists, and thiazolidinediones offer alternative or adjunctive strategies, especially for patients with additional metabolic risk factors or obesity Mangan2018Rendell2020Hostalek2015+1 MORE.
Conclusion
Pharmacological treatment of prediabetes is effective in improving insulin sensitivity, beta-cell function, and reducing the risk of progression to type 2 diabetes. Metformin remains the first-line therapy, but other agents—including SGLT2 inhibitors, GLP-1 receptor agonists, thiazolidinediones, and select natural products—are emerging as valuable options, particularly for patients with specific risk profiles or comorbidities. The choice of therapy should be individualized, considering efficacy, safety, patient characteristics, and the potential for long-term adherence Mangan2018Velazquez2022Rendell2020+5 MORE.
Sources and full results
Most relevant research papers on this topic